Innate Pharma

Innate Pharma announces its financial calendar for 2017

January 4, 2017

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2017, which is set as follows: March 7, 2017 : Publication of 2016 financial statements...

Innate Pharma to participate in the Kempen Life Sciences conference

April 3, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that...

Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) And 2025 Form 20-f Annual Report

April 2, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2025 Universal Registration Document (Document d’enregistrement universel) for...

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers

Innate Pharma announces its financial calendar for 2017

Innate Pharma to participate in the Kempen Life Sciences conference

Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) And 2025 Form 20-f Annual Report

Innate Pharma reports full year 2025 financial results and business update

Innate Pharma announces conference call and webcast for full year 2025 financial results

Number of shares and voting rights of Innate Pharma as of February 19, 2026

Innate pharma to participate in the Leerink Partners Global Healthcare Conference

Number of shares and voting rights of Innate Pharma as of December 31, 2025

Number of shares and voting rights of Innate Pharma as of December 18, 2025

Innate Pharma releases its 2026 financial calendar